Core Insights - Xeriant, Inc. has made significant progress in 2025, particularly with its NEXBOARD™ eco-friendly composite building panel, which integrates nanotechnology for enhanced thermal performance and fire resistance, positioning the company for a commercial launch in the green construction materials market projected to reach $1.8 trillion by 2030 [2][5] Group 1: Company Developments - The successful pilot production run and internal testing of NEXBOARD™ demonstrate its superior fire resistance under extreme temperatures, paving the way for certification and market entry [2] - Xeriant aims to expand its nanotechnology product portfolio and establish a technology ecosystem through its Factor X Research Group, focusing on high-impact technologies such as nanomaterials, artificial intelligence, quantum computing, and data science [3] Group 2: Future Vision - The company envisions becoming a collaborative force in the technology landscape, addressing global challenges in construction, aerospace, and security [3] - Xeriant is working towards a Nasdaq uplisting and revenue generation, emphasizing its commitment to sustainable and innovative technologies [4]

Core Viewpoint - Nanobiotix has been admitted to the CAC Mid 60 and SBF 120 indices, enhancing its visibility among institutional investors and strengthening its presence in European equity markets [1][2][3]. Group 1: Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on physics-based therapeutic approaches for cancer and other major diseases [1][4]. - The company is headquartered in Paris, France, and has been listed on Euronext Paris since 2012 and on Nasdaq since December 2020 [5]. - Nanobiotix holds over 25 umbrella patents related to three nanotechnology platforms, which include applications in oncology, bioavailability, and disorders of the central nervous system [6]. Group 2: Market Impact - Inclusion in the CAC Mid 60 and SBF 120 indices is expected to broaden Nanobiotix's visibility and increase exposure to index-linked investment strategies [2]. - The admission reflects the financial markets' confidence in Nanobiotix's long-term strategy and the potential of its nanotherapeutic solutions [3].

Group 1: Company Overview - Taiwan Semiconductor Manufacturing Company Limited (TSM) is the world's largest dedicated contract chip producer, holding a mid-60% market share in 2024 [6] - The company utilizes its own integrated circuit designs to manufacture chips for clients, benefiting from the global shift of semiconductor companies from integrated device manufacturers to fabless designers [6] Group 2: Financial Projections - Bernstein has increased its price target for TSM from $290 to $330, maintaining an Outperform rating [2] - The firm projects TSM's chip-on-wafer-on-substrate capacity to reach 125,000 wafers per month by the end of 2026, aligning with Nvidia's requirements for upcoming projects [2] - Sales for TSM are anticipated to grow by 20% in 2027 and 23% in fiscal 2026 [2] Group 3: Legal Issues - TSM has filed a lawsuit against Wei-Jen Lo, a former senior vice president who joined Intel, citing potential misuse of trade secrets and breach of a non-compete agreement [3] - The Taiwan economy ministry is monitoring the situation and will assist in determining if there are violations of the National Security Act or infringement of core technologies [4] - Lo has a significant background in chip production, having contributed to the mass production of 5-nm, 3-nm, and 2-nm chips during his 21 years at TSM [5]

Core Insights - Broadcom Inc. (NASDAQ:AVGO) is recognized as one of the top nanotechnology stocks to invest in currently [1] - Oppenheimer analyst Rick Schafer has raised the price target for Broadcom from $400 to $435, maintaining an Outperform rating ahead of the company's fourth-quarter reports [2] - The company is expected to see positive outcomes and guidance, particularly from its networking and AI compute divisions [2] Financial Projections - Oppenheimer anticipates an increase in quantities of the next-generation Tomahawk 6 chip in the second half of 2026, which is expected to enhance growth and improve gross margins [3] - Broadcom aims for a market potential of $60 billion to $90 billion by 2027 in networking chips and data-center processors, particularly for clients like Google and OpenAI [3] Strategic Partnerships - Microsoft is reportedly in discussions with Broadcom to co-design specialized chips to address the rising demand for AI [4]

Group 1 - Thermo Fisher Scientific Inc. (TMO) is recognized as one of the 13 Best Nanotechnology Stocks to Buy Now [1] - Morgan Stanley analyst Kallum Titchmarsh has set a price target of $670 for TMO, indicating an optimistic outlook for the company, particularly in the Life Science Tools and Diagnostics markets [2] - The company has expanded its bioprocessing facilities in Incheon, Korea, and Singapore, and opened a new Bioprocess Design Center in Hyderabad, India, enhancing its capabilities in delivering biologics and vaccines [3][4] Group 2 - The expansion of facilities is aimed at improving the delivery of biologics, vaccines, and cell and gene treatments, making them more efficient and sustainable [4] - Despite the positive outlook for TMO, there is a caution regarding the recent industry valuation surge, which has led to a more cautious industry outlook from Morgan Stanley [3] - TMO provides a range of life science reagents, diagnostic supplies, and laboratory equipment, positioning itself as a key player in the life sciences sector [5]

Core Insights - Lam Research Corporation (NASDAQ:LRCX) is recognized as one of the 13 best nanotechnology stocks to invest in currently [1] - Analysts have reaffirmed positive ratings for Lam Research, with Bernstein maintaining a buy rating and a price target of $175.00 [2] - Morgan Stanley has increased its price target for Lam Research from $137 to $158, while keeping its wafer fab equipment (WFE) forecast for 2026 at $129 billion, indicating an 11% year-over-year growth [3] Company Developments - Lam Research announced the opening of a new $65 million office facility in Tualatin, Oregon, which spans 120,000 square feet and can accommodate up to 700 workspaces [4] - The new facility is part of Lam's multi-year Silicon Forest strategy aimed at enhancing research and development capabilities to support the anticipated growth of the $1 trillion global semiconductor industry [4] - The senior vice president of Lam Research highlighted that the new facility will enhance the company's ability to advance process development and semiconductor production machinery [5] Market Position - Lam Research is a significant supplier of semiconductor wafer fabrication equipment, having shifted from a focus primarily on memory chip manufacturers to gaining substantial market share in logic chip equipment [5]

Group 1 - ASML Holding N.V. is recognized as one of the best nanotechnology stocks to invest in [1] - Citi analyst Andrew Gardiner raised the price target for ASML to EUR 1,200 from EUR 1,050, maintaining a Buy recommendation due to strong growth driven by AI demand [2] - Deutsche Bank also maintained a Buy recommendation, increasing its price target for ASML to EUR 1,150 from EUR 1,000, highlighting ASML's unique position in the extreme ultraviolet lithography market [3] Group 2 - ASML's market dominance is facing challenges from startups, with the Trump administration planning to invest up to $150 million in chip laser startup XLight, which aims to develop energy-efficient technology [4] - Other companies, such as Substrate, are exploring competing technologies in advanced chip manufacturing [4]

Group 1: Company Overview - KLA Corporation (NASDAQ:KLAC) is recognized as one of the best nanotechnology stocks to buy currently [1] - KLA Corporation is a leading producer of semiconductor wafer fabrication equipment globally [6] Group 2: Financial Performance - KLA Corporation reported a record cash flow of $1.066 billion in the last quarter [5] - The company disclosed a total capital return of $799 million, which included $254 million in dividends and $545 million in share repurchases over the previous 12 months [5] Group 3: Market Position and Forecast - Morgan Stanley has maintained an Equal Weight rating on KLA Corporation and increased its price objective from $1,154 to $1,214 [2] - The semiconductor equipment industry's process diagnostic and control market is dominated by KLA Corporation, which has a wide economic moat and is well-positioned for future growth according to Morningstar analysts [4] - Morgan Stanley's 2026 wafer fab equipment (WFE) forecast remains at $129 billion, reflecting an 11% year-over-year increase, with a raised 2027 estimate of $145 billion, a 13% increase from the previous year, driven by demand from TSMC and DRAM [3]

Core Viewpoint - 3M Company (NYSE:MMM) is recognized as one of the best nanotechnology stocks to invest in currently [1] Group 1: Analyst Ratings and Price Targets - Barclays has maintained an Overweight rating on 3M Company and increased its price target from $180 to $190, reflecting a positive outlook for 2026 despite low projections for most end-markets [2] - Deutsche Bank has downgraded its rating on 3M Company from Buy to Hold, lowering its price target from $199 to $178, citing limited upside potential through 2028 due to a reduced valuation gap with competitors [3] Group 2: Financial Performance - In the latest quarter, 3M Company reported adjusted earnings of $2.19 per share, a 10% increase from the previous year, surpassing Wall Street's consensus of $2.07 [4] - The company has raised its 2025 adjusted earnings guidance to a range of $7.95 to $8.05 per share, up from a previous range of $7.75 to $8.00, driven by strong organic growth and margin expansion [4] Group 3: Company Overview - 3M Company is a multinational corporation that offers a wide range of products, including sponges and respirators [4]

Registration No. 333-291598 As filed with the U.S. Securities and Exchange Commission on December 11, 2025. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) England and Wales 2834 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (IRS Em ...